{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-013498","form_type":"8-K","ticker":"PLX","cik":"0001006281","company_name":"Protalix BioTherapeutics, Inc.","filed_at":"2026-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.388946+00:00","generated_at":"2026-05-16T03:11:52.114225+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.01,"calibrated_materiality_score":0.01,"confidence":"low","headline":"Protalix BioTherapeutics posts February 2026 corporate presentation to website; no material new data disclosed","bullets":["Company filed Form 8-K indicating a corporate presentation was posted on February 11, 2026.","Exhibit 99.1 consists solely of a title slide with no specific financial or pipeline updates.","No new guidance, clinical data, or business developments were provided in the furnished exhibit.","Investors would need to access the full presentation on the company website for details."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-013498","json":"https://secwatch.observer/filing/0001104659-26-013498.json","markdown":"https://secwatch.observer/filing/0001104659-26-013498.md","text":"https://secwatch.observer/filing/0001104659-26-013498.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926013498/0001104659-26-013498-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926013498/plx-20260211x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T03:11:52.114225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}